Supercritical fluid chromatography for therapeutic drug monitoring of immunosuppressants

Selectivity for cyclosporine a, fk 506 (tacrolimus), and rapamycin

Steven H Y Wong, Bharti Ghodgaonkar, Peter Fong, Brendan Campbell, James F. Burdick, Fouad Boctor

Research output: Contribution to journalArticle

Abstract

Clinical monitoring of cyclosporine A (CsA) in whole blood is currently performed by either immunoassays or high-performance liquid chromatography. A new immunosuppressant, FK 506 -Tacrolimus, is currently undergoing multi-centers clinical trial for liver transplant, while active research and clinical studies are being performed for another new immunosuppressant, raparnycin. The present study investigated their chromatographic selectivities by supercritical fluid chromatography, in comparison to HPLC. Feasibility studies were performed for the analyses of extracts of whole blood samples, after solid-phase extraction. SFC analyses were performed by using an open tubular SB-biphenyl capillary column, C02as the mobile phase, pressure programming from 100 to 300 atmospheres, separation temperature of 70® C, and FID detection. CsA eluted after the internal standard CsD, while FK 506 tautomer eluted after FK 506. From the “ reversal’’ of elution order as compared to reversed-phase LC, the selectivity of the above column with CO2 as the mobile phase was characterized as “ normal-phase HPLC-like “. Analysis of extracts of CsA patient’s samples, and FK 506 spiked whole blood samples showed that the current SFC procedure did not achieve sufficient sensitivity limit for clinical therapeutic drug monitoring.

Original languageEnglish (US)
Pages (from-to)2093-2109
Number of pages17
JournalJournal of Liquid Chromatography
Volume17
Issue number10
DOIs
StatePublished - Jun 1 1994

Fingerprint

Supercritical Fluid Chromatography
Drug Monitoring
Tacrolimus
Sirolimus
Immunosuppressive Agents
Cyclosporine
Monitoring
Blood
Pharmaceutical Preparations
High Pressure Liquid Chromatography
Transplants
Solid Phase Extraction
High performance liquid chromatography
Feasibility Studies
Atmosphere
Immunoassay
Liver
Clinical Trials
Pressure
Temperature

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Supercritical fluid chromatography for therapeutic drug monitoring of immunosuppressants : Selectivity for cyclosporine a, fk 506 (tacrolimus), and rapamycin. / Wong, Steven H Y; Ghodgaonkar, Bharti; Fong, Peter; Campbell, Brendan; Burdick, James F.; Boctor, Fouad.

In: Journal of Liquid Chromatography, Vol. 17, No. 10, 01.06.1994, p. 2093-2109.

Research output: Contribution to journalArticle

@article{5f43a65f30704b0cb351d2cfce400cd8,
title = "Supercritical fluid chromatography for therapeutic drug monitoring of immunosuppressants: Selectivity for cyclosporine a, fk 506 (tacrolimus), and rapamycin",
abstract = "Clinical monitoring of cyclosporine A (CsA) in whole blood is currently performed by either immunoassays or high-performance liquid chromatography. A new immunosuppressant, FK 506 -Tacrolimus, is currently undergoing multi-centers clinical trial for liver transplant, while active research and clinical studies are being performed for another new immunosuppressant, raparnycin. The present study investigated their chromatographic selectivities by supercritical fluid chromatography, in comparison to HPLC. Feasibility studies were performed for the analyses of extracts of whole blood samples, after solid-phase extraction. SFC analyses were performed by using an open tubular SB-biphenyl capillary column, C02as the mobile phase, pressure programming from 100 to 300 atmospheres, separation temperature of 70{\circledR} C, and FID detection. CsA eluted after the internal standard CsD, while FK 506 tautomer eluted after FK 506. From the “ reversal’’ of elution order as compared to reversed-phase LC, the selectivity of the above column with CO2 as the mobile phase was characterized as “ normal-phase HPLC-like “. Analysis of extracts of CsA patient’s samples, and FK 506 spiked whole blood samples showed that the current SFC procedure did not achieve sufficient sensitivity limit for clinical therapeutic drug monitoring.",
author = "Wong, {Steven H Y} and Bharti Ghodgaonkar and Peter Fong and Brendan Campbell and Burdick, {James F.} and Fouad Boctor",
year = "1994",
month = "6",
day = "1",
doi = "10.1080/10826079408013534",
language = "English (US)",
volume = "17",
pages = "2093--2109",
journal = "Journal of Liquid Chromatography and Related Technologies",
issn = "1082-6076",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Supercritical fluid chromatography for therapeutic drug monitoring of immunosuppressants

T2 - Selectivity for cyclosporine a, fk 506 (tacrolimus), and rapamycin

AU - Wong, Steven H Y

AU - Ghodgaonkar, Bharti

AU - Fong, Peter

AU - Campbell, Brendan

AU - Burdick, James F.

AU - Boctor, Fouad

PY - 1994/6/1

Y1 - 1994/6/1

N2 - Clinical monitoring of cyclosporine A (CsA) in whole blood is currently performed by either immunoassays or high-performance liquid chromatography. A new immunosuppressant, FK 506 -Tacrolimus, is currently undergoing multi-centers clinical trial for liver transplant, while active research and clinical studies are being performed for another new immunosuppressant, raparnycin. The present study investigated their chromatographic selectivities by supercritical fluid chromatography, in comparison to HPLC. Feasibility studies were performed for the analyses of extracts of whole blood samples, after solid-phase extraction. SFC analyses were performed by using an open tubular SB-biphenyl capillary column, C02as the mobile phase, pressure programming from 100 to 300 atmospheres, separation temperature of 70® C, and FID detection. CsA eluted after the internal standard CsD, while FK 506 tautomer eluted after FK 506. From the “ reversal’’ of elution order as compared to reversed-phase LC, the selectivity of the above column with CO2 as the mobile phase was characterized as “ normal-phase HPLC-like “. Analysis of extracts of CsA patient’s samples, and FK 506 spiked whole blood samples showed that the current SFC procedure did not achieve sufficient sensitivity limit for clinical therapeutic drug monitoring.

AB - Clinical monitoring of cyclosporine A (CsA) in whole blood is currently performed by either immunoassays or high-performance liquid chromatography. A new immunosuppressant, FK 506 -Tacrolimus, is currently undergoing multi-centers clinical trial for liver transplant, while active research and clinical studies are being performed for another new immunosuppressant, raparnycin. The present study investigated their chromatographic selectivities by supercritical fluid chromatography, in comparison to HPLC. Feasibility studies were performed for the analyses of extracts of whole blood samples, after solid-phase extraction. SFC analyses were performed by using an open tubular SB-biphenyl capillary column, C02as the mobile phase, pressure programming from 100 to 300 atmospheres, separation temperature of 70® C, and FID detection. CsA eluted after the internal standard CsD, while FK 506 tautomer eluted after FK 506. From the “ reversal’’ of elution order as compared to reversed-phase LC, the selectivity of the above column with CO2 as the mobile phase was characterized as “ normal-phase HPLC-like “. Analysis of extracts of CsA patient’s samples, and FK 506 spiked whole blood samples showed that the current SFC procedure did not achieve sufficient sensitivity limit for clinical therapeutic drug monitoring.

UR - http://www.scopus.com/inward/record.url?scp=0028167425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028167425&partnerID=8YFLogxK

U2 - 10.1080/10826079408013534

DO - 10.1080/10826079408013534

M3 - Article

VL - 17

SP - 2093

EP - 2109

JO - Journal of Liquid Chromatography and Related Technologies

JF - Journal of Liquid Chromatography and Related Technologies

SN - 1082-6076

IS - 10

ER -